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The aim of this research was to study the influence of GSTP1 A313G polymorphism on susceptibility, chemothe-
rapy-related toxicity and prognosis of Hodgkin’s lymphoma in Ukrainian patients. Methods. The polymorphic
variants of GSTP1 gene were analyzed using Allelic Discrimination Real-Time PCR. Results. The GSTP1 poly-
morphism is not directly involved in the development of Hodgkin’s lymphoma and chemotherapy-related toxi-
city, but homozygous wild genotype of this gene is associated with a worse clinical response to the therapy and a
higher risk of relapse. Conclusions. The investigation of GSTP1 polymorphism is very promising, since it might
provide a possible application of this genetic marker as an independent prognostic factor of Hodgkin’s
lymphoma.
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Introduction. Hodgkin’s lymphoma (HL) represents
about 0.5–1 % of all malignancies and about 30 % of all 
lymphomas in the residents of developing countries.
The morbidity of HL has two age-specific peaks: the
first comprises the age between 15 and 35 years, while
the second one is observed after the age of 50–60 years. 
In the age category of 15–24 years every sixth oncolo-
gical diagnosis is HL [1, 2]. In Ukraine there is a steady
upward trend in the incidence of malignant lympho-
mas, the rate of growth ranges from 4.2 % to 8.1 % in
different regions of Ukraine [3].
Over more than 150-year history since the descrip-
tion of the first cases of HL till today scientists have fa-
ced many difficulties and contradictories from the recog-
nition of absolute fatality of the disease to its potential
curability. Even the first authors, who described HL,
paid much attention to the diversity of clinical course
of the disease – from quick generalization, which led to
the patient’s death in several months, to the torpid pe-
riod that could last for 20 years without treatment. The
advancement of HL treatment is actually determined
by the differential approach to the treatment in different 
risk groups distinguished by unfavorable prognostic
factors. Modern risk-adapted treatment regimens for
HL lead to good control of the disease and high cure ra-
te for the most patients [4].
However, among the patients with different progno-
stic scores the treatment of about 10–20 % still has low
efficiency. In addition, new aggressive treatment prog-
rams are highly toxic. Hence, identification of new bio-
logical and clinical markers that could help to select pa-
tients with a high risk of the treatment failure, remains a
crucial challenge. The pharmacogenetics study indica-
tes that even a tiny diversity in sequence of genome signi-
ficantly influences the individual treatment response, to-
xicity, and survival of the HL patients. Germline poly-
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morphisms in genes that code for the enzymes, invol-
ved in the pharmacodynamics of anticancer agents, are
common and may result in altered drug pharmacokine-
tics [5, 6]. Current treatment regimens for HL include
nitrogen mustards, anthracyclines, vinca alkaloids, and
epipodophylotoxins, which are metabolized by enzy-
mes of the glutathione S-transferase (GST) system.
Glutathione-S-transferase P1 (GSTP1) is a member of
the GST enzyme superfamily. GSTP1 gene is polymor-
phic that is characterized by adenine (A) to guanine (G)
transition of nucleotide 313 in exon 5 (A313G), which
causes isoleucine (Ile) to valine (Val) substitution at po-
sition 105 of the GSTP1 enzyme (Ile105Val), resulting
in three possible genotypes: 313 A/A, 313 A/G or 313
G/G [7]. The proteins encoded by different alleles of
the gene, show different abilities to metabolize carcino- 
gens and anticancer agents. Watson et al. have shown
that the individuals with two GSTP1 313 G alleles have
lower catalytic activity when compared with the indivi-
duals possessing two GSTP1 313 A alleles, whereas an
intermediate activity was reported for the heterozygo-
tes [8]. 
Therefore, genetic polymorphism of GSTP1 could
be essential in the determination of susceptibility to the
toxic effects of chemicals and might also be involved in
the tumor response to anticancer drugs and influence
the clinical outcome [9]. 
In this report we present the results of the study on
the influence of GSTP1 A313G polymorphism on the
susceptibility, chemotherapy-related toxicity and prog-
nosis of HL in Ukrainian patients.
Materials and methods. Patients. The case group
comprised 97 patients with HL (median age: 31 years,
range: 17–62; males: 34, females: 63) treated in the On- 
cohematological Department of National Cancer Insti-
tute from September 2008 to May 2011. HL was diag-
nosed according to the World Health Organization
(WHO) classification, 2008. The patients were catego-
rized by the Ann Arbor staging system and the Interna-
tional Prognostic Score. Anthracycline-based chemo-
therapy: ABVD (adriamycin/doxorubicin, bleomycin,
vinblastine, dacarbazine) or BEACOPP (bleomycin,
etoposide, adriamycin, cyclophosphamide, oncovin/
vincristin, procarbazine, prednisone) were administe-
red as a first-line therapy for all patients enrolled in this
study. According to the randomization, the patients
with stages IIB and III–IV received BEACOPP-14 or
BEACOPP-esc. Radiotherapy was used to treat residu-
al masses of bulky disease for stages III–IV and all in-
jured areas for stages IIA–IIB. The treatment efficacy
was estimated according to the Cheson criteria. Toxici-
ty rate was evaluated with NCI-CTC, V4.0.
A control group included 158 healthy individuals
(median age: 38 years, range: 19–71; 70 males, 88 fema-
les) with a medical history negative to any type of can-
cer and was not related to the patients. 
An informed consent was obtained from both gro-
ups according to the requirements of the Ethical Com-
mission of the National Cancer Institute.
DNA isolation. The blood samples of all individu-
als were collected in citric acid/EDTA anticoagulation
tubes. Plasma was separated from whole blood by cen-
trifugation at 350 g for 10 min and stored at –70 °C.
Genomic DNA was isolated from the plasma samples
using QIAamp® DNA Blood mini Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s recommen-
dations and stored at –70 °C.
Genotype determination. GSTP1 genotypes (c. 313 A >
> G, p. Ile105Val) were determined using Allelic Dis-
crimination Real-Time PCR. Primers and TaqMan-
MGB probes were designed using Assay-by-Design
service («Applied Biosystems», USA): forward pri-
mer: 5'-CCTGGTGGACATGGTGAATG-3'; reverse
primer: 5'-TGGTGCAGATGCTCACATAGTTG-3';
313 G probe FAM-CTGCAAATACGTCTCC-MGB;
313 A probe VIC-TGCAAATACATCTCC-MGB. PCR 
amplification was performed in a volume of 25 ml con-
taining 10 ng of genomic DNA, 12.5 ml 2X Taqman Uni- 
versal PCR Master Mix («Applied Biosystems»),
200 nM probe, and 900 nM primer. 
Cycling conditions were 50 °C for 2 min, 95 °C for 
10 min, followed by 45 cycles at 92 °C for 30 s and
60 °C for 1 min. The fluorescence emission was recor-
ded using ABI Prism 7500 Sequence Detection System
(«Applied Biosystems»); end point plate read measu-
rements allowed performing allelic discrimination
using Sequence Detection System software («Applied
Biosystems»). 
Statistical analysis. The Hardy-Weinberg equilibri-
um was tested with chi-square statistic for the good-
ness-to-fit (one degree of freedom). Multivariate analy- 
sis was performed to assess the associations between
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GSTP1genotypes and HL. Odds ratios (OR) and 95 %
confidence intervals (95 % CI) were used to estimate
the risk of HL development and different grades of toxi-
city after chemotherapy. The clinical characteristics,
treatment outcomes and toxicities in relation to the
GSTP1 polymorphism were compared among the pati-
ents using chi-square, Fisher’s exact tests, correlation
analyses (Spearman and gamma coefficients). The va-
lue was considered as significant at p < 0.05. All compu-
tations were done using the STATISTICA 6.1. soft-
ware (StatSoft, Inc., USA).
Results and discussion. Characteristics of the pa-
tients. The cohort consisted of 97 patients with HL. The 
clinical features of the patients are presented in Table.
For 97 patients the overall response rate was 91.7 % 
(89/97) with a complete response of 77 % (75/97) and a 
partial response – 13.5 % (14/97). Among the patients
who achieved a complete response during the follow-
up (median duration – 18 months; range 6–36 months),
18 had relapses with disease-free period 3–6 months (3
patients), 6–12 months (9 patients) and 12–24 months
(6 patients). 
During the anthracycline-based chemotherapy the pa- 
tients developed some degree of hematologic (HT) and
nonhematologic (NHT) toxicity (gastrointestinal, cardio-
vascular, hearing, nephro-, neurotoxicity). Among the
patients who received ABVD, severe HT and NHT
(grade 3–4) developed in 14 and 6 % of the cases respec-
tively. The predominant HT types were anemia and neu-
tropenia. For the patients who received BEACOPP-14
severe HT and NHT (grade 3–4) developed in 88 % and 
24 % of the cases respectively, BEACOPP-esc – 87 %
and 19 %. The special feature of BEACOPP-14 treat-
ment was a significantly higher rate of anemia: 25 %
compared with 12.5 % in the group of BEACOPP-esc.
The most frequent NHT for all patients were nausea
and vomiting. 
GSTP1 polymorphism. GSTP1 genotype was as-
sessed for 97 patients with Hodgkin’s lymphoma, 46
(47.4 %) of which were homozygous of the A/A GSTP1 
genotype, 38 (39.2 %) were heterozygous (A/G), 13
(13.4 %) were homozygous of the G/G genotype; and
for 158 healthy blood donors, 76 (48.1 %) of which
were homozygous of the A/A GSTP1 genotype, 63
Variable Patients Variable Patients
Age at diagnosis (years) Ann Arbor stage
   < 45 72    IA–IIA 33
   > 45 15    IIB–IV 64
Gender B symptoms
   Male 34    No 47
   Female   63    Yes 52
Histotype Bulky disease 
   cHL:      No 49
   – nodular sclerosis 40    Yes 58
   – mixed cellularity 31 Complete response after 1st line treatment 
   – lymphocyte rich 7    Yes 75
   – lymphocyte depletion 8    No 22
   Nodular lymphocyte- predominant HL 2 Relapse from complete response 
   Indefinite 9    Yes 18
– –    No 57
Patients characteristics
(39.9 %) – heterozygous (A/G), 19 (12 %) – homozy-
gous of the G/G genotype. 
The distribution of the GSTP1 genotypes in both
control and studied patient groups did not differ signi-
ficantly from that predicted by the Hardy-Weinberg
distribution. The observed G allele frequency was 0.32, 
similarly to the previous reports on allele frequencies
for healthy Caucasians [10, 11]. The obtained results
suggest that the A313G polymorphism of the GSTP1
gene is not directly involved in the development of HL. 
GSTP1 genotypes and alleles distribution for the HL 
patients and healthy Ukrainian are presented in Fig. 1.
We did not notice the association between demogra-
phic (age and gender), clinical and pathologic characte- 
ristics, including histotype, the stage of the disease, the
presence of B symptoms, bulky disease characteristics
of the patients with GSTP1 genotypes. 
Significant relationship between chemotherapy-re- 
lated toxicity for the patients with Hodgkin’s lympho-
ma and GSTP1 genotype was not revealed, although
for the patients with G/G genotype severe hematologi-
cal toxicity was  slightly more often.
We have observed a correlation between GSTP1
polymorphism and prognosis of HL: A/A genotype of
GSTP1 gene can be considered as an independent un-
favorable prognostic factor of HL. A complete respon-
se rate after the first-line therapy was better for the pati- 
ents with the A/G or G/G genotype  in comparison with
the patients with homozygous wild genotype (84 %
(43/51) versus 70 % (32/46), p = 0.066, correlation ana- 
lyses, gamma coefficient). Progression of the disease
during the therapy was observed for 4 % (2/46) of the
patients with the A/A genotype of GSTP1 gene, while it
was not noticed for the other genotype (Fig. 2).
We also analyzed how GSTP1 polymorphism influ-
ences the chemotherapy response and the disease prog-
nosis for the patients grouped according to the stage
(Fig. 3, 4).
As shown in Fig. 3, among the patients with the sta- 
ges IA–IIA, who received ABVD as the first-line the-
rapy, the complete response was achieved in 92.3 %
(12/13) of the cases with A/G + G/G genotypes and
only in 65 % (13/20) – with A/A. Moreover, we did not
notice the Hodgkin’s lymphoma progression during the 
therapy for the patients with G/G and A/G genotypes,
while the patients with A/A have shown the progression 
in 10 % (2/20) of the cases. The frequency of the disea-
se relapse was almost twice higher for the patients with
homozygous wild genotype (30 % (6/20) A/A versus
16 % (2/13) A/G + G/G). 
For the Hodgkin’s lymphoma patients with stages
IIB + (III–IV) (Fig. 4), who received BEACOPP (14/
esc) as the first-line therapy, the complete response was 
achieved in 82 % (31/38) of the cases with A/G + G/G
genotypes and in 73 % (19/26) with A/A; the partial
response – in 16 % (6/38) of the cases with A/G + G/G
genotypes and in 23 % (6/26) with A/A. The frequency
of the disease relapse was significantly higher for the
patients with homozygous wild genotype (27 % (7/26)
A/A versus 8 % (3/38) A/G + G/G, p = 0.003, correla-
tion analyses, gamma coefficient). 
The obtained results suggest that the A313G poly-
morphism of the GSTP1 gene is not directly involved in 
the development of HL and chemotherapy-related to-
xicity, but homozygous wild genotype of this gene
(A/A) is associated with a worse clinical response to the
therapy and a higher risk of the relapse for the HL pa-
tients independently from the stage of the disease.
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Fig. 1. GSTP1 genotypes and alleles distribution for the HL patients
and healthy Ukrainian: 1 – G/G; 2 – A/G; 3 – A/A; 4 – A; 5 – G  
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Fig. 2. GSTP1 genotype and clinical response to the therapy in Hodg-
kin’s lymphoma patients: 1 – A/A; 2 – A/G; 3 – G/G
We assume that the association of A/A with unfa-
vorable prognosis of HL may be attributed to a higher
activity of the wild allele towards anticancer agents
metabolism, as well as to its higher effect on the favou-
ring tumor cell survival when compared with the va-
riant allele, as previously reported [8]. Recently, Hol-
ley et al. have demonstrated that the wild allele protects 
the cells against apoptosis through a JNK-independent
mechanism [12]. 
The prognostic impact of GSTP1 polymorphisms
appears to vary according to the cancer type. Recently,
the GSTP1 313 G/G genotype has been associated with
a favorable prognosis following chemotherapy with the 
drugs known to be GSTP1 substrates in a variety of ma- 
lignancies, such as pediatric acute lymphoblastic leuke-
mia, myeloma, breast and colon cancer [6, 13–15]. The
influence of GSTP1 polymorphism on the effective-
ness of HL therapy has been previously analyzed by
other authors with contradictory results [16–19]. The
main difference has been associated with the different
presentation of HL stages and clinical outcome of the
patients. 
Our results are in line with the previous reports of
Italian researchers, which noticed the association of
GSTP1 homozygous wild genotype with unfavorable
outcome of HL patients [16, 17]. At the same time, some
authors did not find any correlation between GSTP1
polymorphism and HL prognosis in Caucasian patients
[6]. The contradictive results might be due to the fact
that small cohorts of patients have been analyzed along
with the socioeconomic factors and late diagnosis in
some countries. 
Conclusions. Further research of the pharmacoge-
netic factors, such as GSTP1 polymorphism, including
an analysis of larger cohorts of HL patients, may pro-
vide the understanding of molecular mechanisms of the 
development and progression of disease and help to esti-
mate the individual detoxication potential that may in-
fluence the treatment response, susceptibility to the to-
xic effects of chemotherapy, and clinical outcome of
the patients. 
І. А. Кря чок, Н. М. Хра но вська, Н. М. Свер гун, К. С. Філо нен ко, 
О. І. Но во сад, І. Б. Ти то рен ко, А. В. Мар тин чик, Г. О. Гу ба ре ва, 
Т. В. Каднікова, О. M. Алексик, Є. В. Ку ще вий, Я. В. Пас ту шен ко
Досліджен ня впли ву поліморфізму гена GSTP1 A313G на 
ви ник нен ня лімфо ми Ходжкіна, ток сичність хіміот е рапії 
та пе ребіг за хво рю ван ня 
Ре зю ме
Мета. Дослідити поліморфізм гена GSTP1 A313G і виз на чи ти
його вплив на ви ник нен ня лімфо ми Ходжкіна, ток сичність хіміо-
те рапії, а та кож на пе ребіг за хво рю ван ня. Ме то ди. Поліморфні
варіанти гена GSTP1 аналізу ва ли ме то дом алель-спе цифічної
ПЛР з де текцією ре зуль татів у ре жимі ре аль но го часу. Ре зуль -
та ти. Вста нов ле но, що го мо зи гот ний тип успад ку ван ня але ля
ди ко го типу – ге но тип A/A – по в’я за ний з не спри ят ли вим про гно -
зом пе ребігу лімфо ми Ходжкіна: гіршою відповіддю на те рапію і
вірогідністю по я ви ре ци дивів. Вис нов ки. Пер спек тив ним на -
прям ком по шу ку чин ників впли ву на пе ребіг хво ро би є вив чен ня
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Relapse Fig. 3. Clinical response to the therapy (a: 1 –
A/A; 2 – A/G + G/G) and prognosis of the di-
sease (b, c) for the patients with Hodgkin’s
lymphoma stage IA–IIA according to GSTP1
genotype (b – A/A; c – A/G + G/G)
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Fig. 4. Clinical response to the therapy (a: 1 –
A/A; 2 – A/G + G/G) and prognosis of the di-
sease (b, c) for the patients with Hodgkin’s lym-
phoma stages IIB–IV according to GSTP1 ge-
notype (b – A/A; c – A/G + G/G) 
поліморфізму гена GSTP1, який у май бут ньо му може бути ви ко -
рис та ний як «фак тор ри зи ку» при фор му ванні про гнос тич них
груп хво рих та ви борі так ти ки ліку ван ня.
Клю чові сло ва: лімфо ма Ходжкіна, поліморфізм, ген GSTP1. 
И. А. Кря чок, Н. Н. Хра нов ская, Н. Н. Свер гун, К. С. Фи ло нен ко, 
О. И. Но во сад, И. Б. Ти то рен ко, А. В. Мар тын чик, А. А. Гу ба ре ва,
Т. В. Кад ни ко ва, Е. M. Алексик, Е. В. Ку ще вой, Я. В. Пас ту шен ко
Иссле до ва ние вли я ния по ли мор физ ма гена GSTP1 A313G на 
воз ник но ве ние лим фо мы Ход жки на, ток сич ность хи ми о те ра пии
и те че ние за бо ле ва ния
Ре зю ме 
Цель. Иссле до вать по ли мор физм гена GSTP1 A313G и опре де -
лить его вли я ние на воз ник но ве ние лим фо мы Ход жки на, ток сич -
ность хи ми о те ра пии, а так же на те че ние за бо ле ва ния. Мето-
ды. По ли мор фные ва ри ан ты гена GSTP1 ана ли зи ро ва ли ме то дом 
ал лель-спе ци фи чес кой ПЦР с де тек ци ей  ре зуль та тов в ре жи ме
ре аль но го вре ме ни. Ре зуль та ты. Уста нов ле но, что го мо зи гот -
ный тип на сле до ва ния ал ле ля ди ко го типа – ге но тип A/A – ассо-
ци и ро ван с не бла гоп ри ят ным про гно зом те че ния лим фо мы Ходж-
кина: худ шим от ве том на ле че ние и ве ро ят нос тью по яв ле ния ре -
ци ди вов. Вы во ды. Пер спек тив ным на прав ле ни ем по ис ка при чин,
об услов ли ва ю щих те че ние бо лез ни, яв ля ет ся из уче ние по ли мор -
физ ма гена GSTP1, ко то рый в бу ду щем, воз мож но, бу дет ис поль -
зо ван как «фак тор риc ка» при фор ми ро ва нии про гнос ти чес ких
групп боль ных и вы бо ре так ти ки ле че ния.
Клю че вые сло ва: лим фо ма Ход жки на, по ли мор физм, ген GSTP1.
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